收盘价:Aug 10, 16:00:00 GMT-4
盘后:Aug 10, 20:09:12 GMT-4
No Data Yet
Johnson & Johnson's Ottava surgical robot received FDA de novo authorization for general surgery, challenging Intuitive Surgical's dominance of the robotic surgery market.
Johnson & Johnson announced FDA Priority Review for subcutaneous amivantamab (RYBREVANT FASPRO) in recurrent or metastatic head and neck squamous cell carcinoma.
Johnson & Johnson completed its $1 billion acquisition of Firefly Bio, adding a degrader antibody conjugate platform to target KRAS-driven solid tumors.
Johnson & Johnson announced a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases, joining a $14 billion industry race.
Johnson & Johnson 的市盈率是 22.8735
Mr. Joaquin Duato 是 Johnson & Johnson 的 Chairman of the Board,自 2016 加入公司。
JNJ 的当前价格为 $261.81,在上个交易日 下降 了 0%。
Johnson & Johnson 属于 Pharmaceuticals 行业,该板块是 Health Care
Johnson & Johnson 的当前市值是 $630.9B
据华尔街分析师称,共有 27 位分析师对 Johnson & Johnson 进行了分析师评级,包括 5 位强烈买入,11 位买入,15 位持有,0 位卖出,以及 5 位强烈卖出